Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25294
Title: Association of β-amyloid level, clinical progression and longitudinal cognitive change in normal older individuals.
Austin Authors: van der Kall, Laura M;Truong, Thanh;Burnham, Samantha C;Doré, Vincent ;Mulligan, Rachel S ;Bozinovski, Svetlana ;Lamb, Fiona ;Bourgeat, Pierrick;Fripp, Jurgen;Schultz, Stephanie;Lim, Yen Y;Laws, Simon M;Ames, David;Fowler, Christopher;Rainey-Smith, Stephanie R;Martins, Ralph N;Salvado, Olivier;Robertson, Joanne;Maruff, Paul;Masters, Colin L ;Villemagne, Victor L ;Rowe, Christopher C 
Affiliation: Edith Cowan University, Perth, Australia
University of Melbourne, Melbourne, Australia
Washington University, St. Louis, USA
CSIRO, Melbourne, Australia
The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
Austin Health
CSIRO, Brisbane, Australia
Austin Health, Melbourne, Australia
Issue Date: 2-Feb-2021
metadata.dc.date: 2020-11-12
Publication information: Neurology 2021; 96(5): e662-e670
Abstract: To determine the effect of Aβ level on progression risk to MCI or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. All CN from the Australian Imaging Biomarkers and Lifestyle study (AIBL) with Aβ PET and ≥3 years follow-up were included (n=534; age 72±6 yrs; 27% Aβ positive; follow-up 5.3±1.7 yrs). Aβ level was divided using the standardised 0-100 Centiloid scale: <15 CL negative, 15-25 CL uncertain, 26-50 CL moderate, 51-100 CL high, >100 CL very high, noting >25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess risk of progression and cognitive decline. Aβ levels in 63% were negative, 10% uncertain, 10% moderate, 14% high and 3% very high. Fifty-seven (11%) progressed to MCI or dementia. Compared to negative Aβ, the hazard ratio for progression for moderate Aβ was 3.2 (95% CI 1.3-7.6; p<0.05), for high was 7.0 (95% CI 3.7-13.3; p<0.001) and for very high was 11.4 (95% CI 5.1-25.8; p<0.001). Decline in cognitive composite score was minimal in the moderate group (-0.02 SD/year, p=0.05) while the high and very high declined substantially (high -0.08 SD/year, p<0.001; very high -0.35 SD/year p<0.001). The risk of MCI or dementia over 5 years in older CN is related to Aβ level on PET, 5% if negative vs 25% if positive but ranging from 12% if 26-50 CL to 28% if 51-100 CL and 50% if >100 CL. This information may be useful for dementia risk counselling and aid design of preclinical AD trials.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25294
DOI: 10.1212/WNL.0000000000011222
ORCID: 0000-0001-5359-4322
0000-0002-4355-7082
PubMed URL: 33184233
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

30
checked on Apr 15, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.